Decreasing risk and increasing patient choice

75% of patients want a drug-free depression treatment due to lack of efficacy or serious medication side effects1.

With no major side effects reported, provide your patients another choice with Flow2.

family in sofa
Graph 3 - minor side-effects

No major adverse events2.

Unlike medications, the Flow tDCS treatment directly targets the physical root cause of depression without affecting other areas of the body and internal systems.

Approved for at-home use across the UK and EU

FDA Breakthrough device designation

FDA breakthrough device designation for at-home depression treatment


Approved by the British Standards Institutions (BSI)


Class IIa medical device CE-marked. Approved for in the EU and UK


Tested according to IEC 60601 for electrical medical device safety

headset -shop

Minor side effects reported

Flow’s real world data shows that the majority of Flow users do not experience any side effects, but less than 2% have reported2:

  • Skin irritation (<1%)
  • Headaches (~1%)
  • Tinnitus (<0.5%)

Backed by decades of tDCS research

tDCS is not a new treatment for depression. The Flow treatment, both the tDCS headset and behavioural therapy app utilise clinically validated techniques for treating depression.

Across 20+ randomized controlled trials, tDCS has been shown to be superior to placebo/sham4 and no serious adverse events have been observed5.

mother daughter -shop

Seeking alternatives without crippling side effects

Although some patients are comfortable treating their depression with medication, surveys suggest the majority are not1.

Patients are increasingly looking for alternatives to drug therapy. Studies show that antidepressants can affect libido, cause erectile dysfunction, fatigue, insomnia, weight gain, as well as other gastro issues6-8. Patients are looking to feel better but no longer at the expense of these other areas of their life.


McHugh RK, et al. J Clin Psychiatry. 2013;74(6):595-602. 2. Data on File. 3. Read J, Williams J. Curr Drug Saf. 2018;13(3):176-186. 4. Razza LB, et al. Depress Anxiety. 2020;37:594-608. 5. Chhabra Harleen et al. Psychiatry Res; 2020. 6. Khawam EA, et al. Cleve Clin J Med. 2006;73(4):351-3, 356-61. 7. Cascade E, et al. Psychiatry (Edgmont). 2009;6(2):16-8. 8. Carvalho AF, et al. Psychother Psychosom. 2016;85(5):270-88. 9. Brunoni AR, et al. N Engl J Med. 2017; 376:2523-2533.